Receptos rallies on Celgene, Teva buyout rumors

Receptos (RCPT +20.3%) soars after Calcalist says Celgene (CELG) and Teva (TEVA) are bidding for the company.

Bids are reportedly in the $700-800M range.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs